Laura Herdman
University of Oxford
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Laura Herdman.
Diabetes | 2015
Alexios S. Antonopoulos; Marios Margaritis; P Coutinho; C Shirodaria; C Psarros; Laura Herdman; Fabio Sanna; R De Silva; Mario Petrou; Rana Sayeed; George Krasopoulos; Regent Lee; Janet E. Digby; Svetlana Reilly; C Bakogiannis; Dimitris Tousoulis; Benedikt M. Kessler; Barbara Casadei; Keith M. Channon; Charalambos Antoniades
Oxidative stress plays a critical role in the vascular complications of type 2 diabetes. We examined the effect of type 2 diabetes on NADPH oxidase in human vessels and explored the mechanisms of this interaction. Segments of internal mammary arteries (IMAs) with their perivascular adipose tissue (PVAT) and thoracic adipose tissue were obtained from 386 patients undergoing coronary bypass surgery (127 with type 2 diabetes). Type 2 diabetes was strongly correlated with hypoadiponectinemia and increased vascular NADPH oxidase–derived superoxide anions (O2˙−). The genetic variability of the ADIPOQ gene and circulating adiponectin (but not interleukin-6) were independent predictors of NADPH oxidase–derived O2˙−. However, adiponectin expression in PVAT was positively correlated with vascular NADPH oxidase–derived O2˙−. Recombinant adiponectin directly inhibited NADPH oxidase in human arteries ex vivo by preventing the activation/membrane translocation of Rac1 and downregulating p22phox through a phosphoinositide 3-kinase/Akt-mediated mechanism. In ex vivo coincubation models of IMA/PVAT, the activation of arterial NADPH oxidase triggered a peroxisome proliferator–activated receptor-γ–mediated upregulation of the adiponectin gene in the neighboring PVAT via the release of vascular oxidation products. We demonstrate for the first time in humans that reduced adiponectin levels in individuals with type 2 diabetes stimulates vascular NADPH oxidase, while PVAT “senses” the increased NADPH oxidase activity in the underlying vessel and responds by upregulating adiponectin gene expression. This PVAT-vessel interaction is identified as a novel therapeutic target for the prevention of vascular complications of type 2 diabetes.
Circulation Research | 2016
Alexios S. Antonopoulos; Marios Margaritis; Sander Verheule; Alice Recalde; Fabio Sanna; Laura Herdman; Costas Psarros; Hussein M. Nasrallah; P Coutinho; Ioannis Akoumianakis; Alison C. Brewer; Rana Sayeed; George Krasopoulos; Mario Petrou; Akansha Tarun; Dimitrios Tousoulis; Ajay M. Shah; Barbara Casadei; Keith M. Channon; Charalambos Antoniades
Supplemental Digital Content is available in the text.
Science Translational Medicine | 2017
Alexios S. Antonopoulos; Fabio Sanna; Nikant Sabharwal; Sheena Thomas; Evangelos Oikonomou; Laura Herdman; Marios Margaritis; C Shirodaria; Anna-Maria Kampoli; Ioannis Akoumianakis; Mario Petrou; Rana Sayeed; George Krasopoulos; Constantinos Psarros; Patricia Ciccone; Carl M. Brophy; Janet E. Digby; Andrew D Kelion; Raman Uberoi; Suzan Anthony; Nikolaos Alexopoulos; Dimitris Tousoulis; Stephan Achenbach; Stefan Neubauer; Keith M. Channon; Charalambos Antoniades
Adipocyte size and lipid content in perivascular adipose tissue are inversely associated with coronary inflammation and atherosclerotic plaque burden in human patients. Picturing plaques and imaging inflammation To determine risk of future coronary artery disease, calcium content in vascular plaques is typically evaluated by coronary calcium scoring, which uses computerized tomography (CT) imaging. To detect inflammation and subclinical coronary artery disease (soft, noncalcified plaques), Antonopoulos et al. developed an alternative metric called the perivascular CT fat attenuation index (FAI). The perivascular FAI uses CT imaging of adipose tissue surrounding the coronary arteries to assess adipocyte size and lipid content. Larger, more mature adipocytes exhibit greater lipid accumulation, which is inversely associated with the FAI. Inflammation reduces lipid accumulation and slows preadipocyte differentiation. Imaging pericoronary fat in human patients after myocardial infarction revealed that unstable plaques had larger perivascular FAIs than stable plaques and that the FAI was greatest directly adjacent to the inflamed coronary artery. The perivascular FAI may be a useful, noninvasive method for monitoring vascular inflammation and the development of coronary artery disease. Early detection of vascular inflammation would allow deployment of targeted strategies for the prevention or treatment of multiple disease states. Because vascular inflammation is not detectable with commonly used imaging modalities, we hypothesized that phenotypic changes in perivascular adipose tissue (PVAT) induced by vascular inflammation could be quantified using a new computerized tomography (CT) angiography methodology. We show that inflamed human vessels release cytokines that prevent lipid accumulation in PVAT-derived preadipocytes in vitro, ex vivo, and in vivo. We developed a three-dimensional PVAT analysis method and studied CT images of human adipose tissue explants from 453 patients undergoing cardiac surgery, relating the ex vivo images with in vivo CT scan information on the biology of the explants. We developed an imaging metric, the CT fat attenuation index (FAI), that describes adipocyte lipid content and size. The FAI has excellent sensitivity and specificity for detecting tissue inflammation as assessed by tissue uptake of 18F-fluorodeoxyglucose in positron emission tomography. In a validation cohort of 273 subjects, the FAI gradient around human coronary arteries identified early subclinical coronary artery disease in vivo, as well as detected dynamic changes of PVAT in response to variations of vascular inflammation, and inflamed, vulnerable atherosclerotic plaques during acute coronary syndromes. Our study revealed that human vessels exert paracrine effects on the surrounding PVAT, affecting local intracellular lipid accumulation in preadipocytes, which can be monitored using a CT imaging approach. This methodology can be implemented in clinical practice to noninvasively detect plaque instability in the human coronary vasculature.
European Heart Journal | 2017
Marios Margaritis; Fabio Sanna; George Lazaros; Ioannis Akoumianakis; Sheena Patel; Alexios S. Antonopoulos; Chloe Duke; Laura Herdman; Costas Psarros; Evangelos Oikonomou; C Shirodaria; Mario Petrou; Rana Sayeed; George Krasopoulos; Regent Lee; Dimitris Tousoulis; Keith M. Channon; Charalambos Antoniades
Abstract Aims Experimental evidence suggests that telomere length (TL) is shortened by oxidative DNA damage, reflecting biological aging. We explore the value of blood (BTL) and vascular TL (VTL) as biomarkers of systemic/vascular oxidative stress in humans and test the clinical predictive value of BTL in acute myocardial infarction (AMI). Methods and results In a prospective cohort of 290 patients surviving recent AMI, BTL measured on admission was a strong predictor of all-cause [hazard ratio (HR) [95% confidence interval (CI)]: 3.21 [1.46–7.06], P = 0.004] and cardiovascular mortality (HR [95% CI]: 3.96 [1.65–9.53], P = 0.002) 1 year after AMI (for comparisons of short vs. long BTL, as defined by a T/S ratio cut-off of 0.916, calculated using receiver operating characteristic analysis; P adjusted for age and other predictors). To explore the biological meaning of these findings, BTL was quantified in 727 consecutive patients undergoing coronary artery bypass grafting (CABG), and superoxide (O2.-) was measured in peripheral blood mononuclear cells (PBMNC). VTL/vascular O2.- were quantified in saphenous vein (SV) and mammary artery (IMA) segments. Patients were genotyped for functional genetic polymorphisms in P22ph°x (activating NADPH-oxidases) and vascular smooth muscle cells (VSMC) selected by genotype were cultured from vascular tissue. Short BTL was associated with high O2.- in PBMNC (P = 0.04) but not in vessels, whereas VTL was related to O2.- in IMA (ρ = −0.49, P = 0.004) and SV (ρ = −0.52, P = 0.01). Angiotensin II (AngII) incubation of VSMC (30 days), as a means of stimulating NADPH-oxidases, increased O2.- and reduced TL in carriers of the high-responsiveness P22ph°x alleles (P = 0.007). Conclusion BTL predicts cardiovascular outcomes post-AMI, independently of age, whereas VTL is a tissue-specific (rather than a global) biomarker of vascular oxidative stress. The lack of a strong association between BTL and VTL reveals the importance of systemic vs. vascular factors in determining clinical outcomes after AMI.
The Lancet | 2018
Evangelos Oikonomou; Mohamed Marwan; Milind Y. Desai; Jennifer Mancio; Alaa Alashi; Erika Hutt Centeno; Sheena Thomas; Laura Herdman; Christos P Kotanidis; Katharine E Thomas; Brian P. Griffin; Scott D. Flamm; Alexios S. Antonopoulos; C Shirodaria; Nikant Sabharwal; John Deanfield; Stefan Neubauer; Jemma C. Hopewell; Keith M. Channon; Stephan Achenbach; Charalambos Antoniades
Summary Background Coronary artery inflammation inhibits adipogenesis in adjacent perivascular fat. A novel imaging biomarker—the perivascular fat attenuation index (FAI)—captures coronary inflammation by mapping spatial changes of perivascular fat attenuation on coronary computed tomography angiography (CTA). However, the ability of the perivascular FAI to predict clinical outcomes is unknown. Methods In the Cardiovascular RISk Prediction using Computed Tomography (CRISP-CT) study, we did a post-hoc analysis of outcome data gathered prospectively from two independent cohorts of consecutive patients undergoing coronary CTA in Erlangen, Germany (derivation cohort) and Cleveland, OH, USA (validation cohort). Perivascular fat attenuation mapping was done around the three major coronary arteries—the proximal right coronary artery, the left anterior descending artery, and the left circumflex artery. We assessed the prognostic value of perivascular fat attenuation mapping for all-cause and cardiac mortality in Cox regression models, adjusted for age, sex, cardiovascular risk factors, tube voltage, modified Duke coronary artery disease index, and number of coronary CTA-derived high-risk plaque features. Findings Between 2005 and 2009, 1872 participants in the derivation cohort underwent coronary CTA (median age 62 years [range 17–89]). Between 2008 and 2016, 2040 patients in the validation cohort had coronary CTA (median age 53 years [range 19–87]). Median follow-up was 72 months (range 51–109) in the derivation cohort and 54 months (range 4–105) in the validation cohort. In both cohorts, high perivascular FAI values around the proximal right coronary artery and left anterior descending artery (but not around the left circumflex artery) were predictive of all-cause and cardiac mortality and correlated strongly with each other. Therefore, the perivascular FAI measured around the right coronary artery was used as a representative biomarker of global coronary inflammation (for prediction of cardiac mortality, hazard ratio [HR] 2·15, 95% CI 1·33–3·48; p=0·0017 in the derivation cohort, and 2·06, 1·50–2·83; p<0·0001 in the validation cohort). The optimum cutoff for the perivascular FAI, above which there is a steep increase in cardiac mortality, was ascertained as −70·1 Hounsfield units (HU) or higher in the derivation cohort (HR 9·04, 95% CI 3·35–24·40; p<0·0001 for cardiac mortality; 2·55, 1·65–3·92; p<0·0001 for all-cause mortality). This cutoff was confirmed in the validation cohort (HR 5·62, 95% CI 2·90–10·88; p<0·0001 for cardiac mortality; 3·69, 2·26–6·02; p<0·0001 for all-cause mortality). Perivascular FAI improved risk discrimination in both cohorts, leading to significant reclassification for all-cause and cardiac mortality. Interpretation The perivascular FAI enhances cardiac risk prediction and restratification over and above current state-of-the-art assessment in coronary CTA by providing a quantitative measure of coronary inflammation. High perivascular FAI values (cutoff ≥–70·1 HU) are an indicator of increased cardiac mortality and, therefore, could guide early targeted primary prevention and intensive secondary prevention in patients. Funding British Heart Foundation, and the National Institute of Health Research Oxford Biomedical Research Centre.
Heart | 2018
Ioannis Akoumianakis; Laura Herdman; Marios Margaritis; Rana Sayeed; George Krasopoulos; Mario Petrou; Norbert Tennagels; Paulus Wohlfart; Keith M. Channon; Charalambos Antoniades
Background Insulin may have protective roles in vascular cells, but its vascular effects in patients with atherosclerosis are unknown. Dipeptidyl peptidase 4 (DPP4) inhibitors are a class of insulin-sensitising agents that may regulate vascular responses to insulin in humans. We attempted to determine the direct vascular effects of insulin in humans with atherosclerosis, and explore the effect of DPP4 inhibition on vascular insulin signalling. Methods The study included 613 patients undergoing coronary bypass surgery. Vascular segments (internal mammary arteries (IMA), saphenous veins (SV)) were collected and incubated with insulin glargine active metabolite M1 (insulin), insulin degludec (DEG) and human insulin (HI) (1–100 nM as stated), with or without pre-incubation with KR62436 (a DPP4 inhibitor) at 70 µM. Vascular superoxide (O2.-) was quantified by lucigenin chemiluminescence, while nitric oxide bioavailability was evaluated by quantifying the vasorelaxations to acetylcholine. Circulating DPP4 activity was measured in fasting serum using commercially available kits. Downstream signalling was evaluated by Western blotting for protein phosphorylation. Results Insulin increased NADPH-oxidases-derived O2.- in vessels from patients with or without diabetes, an effect reversed in vascular segments from diabetic patients pre-treated with an oral DPP4 inhibitor (A). In contrast, insulin reduced O2.- in vessels of healthy mice used as controls (not shown). Circulating DPP4 activity was associated with increased vascular NADPH-oxidases activity in the study population (not shown), while ex vivo pre-incubation of human vessels with KR62436 (DPP4-i) reversed the effect of insulin on vascular O2.-, supressing NADPH-oxidases activity (B), improving eNOS coupling (C) and ameliorating endothelial dysfunction in human vessels (D). This was a class effect, replicated using DEG and HI (data not shown). DPP4 inhibition improved downstream insulin signalling by reducing insulin receptor substrate 1 (IRS1) phosphorylation at Ser307, a site linked to molecular insulin resistance (E). The vascular effects of DPP4 inhibition may be regulated via AMPK, since DPP4-i increased AMPK Thr172 phosphorylation while AMPK inhibition with compound C reversed the protective vascular effects of DPP4-I (F). Conclusions We demonstrate for the first time that insulin induces oxidative stress and endothelial dysfunction in vascular segments from patients with atherosclerosis, independently of systemic insulin resistance. This may partially explain the inability of insulin treatment to improve cardiovascular outcomes in patients with moderately elevated blood glucose. Pre-treatment with a DPP4 inhibitor restores local insulin sensitivity modulating the vascular responses to insulin. These findings suggest that vascular sensitisation may be crucial when treating of diabetic patients in secondary prevention.
European Heart Journal | 2015
Marios Margaritis; George Lazaros; Sheena Patel; Laura Herdman; A S Antonopoulos; Ioannis Akoumianakis; Fabio Sanna; Dimitrios Tousoulis; K M Channon; Charalambos Antoniades
The Lancet | 2018
Evangelos Oikonomou; Mohamed Marwan; D Y Milind; Jennifer Mancio; Alaa Alashi; E Hutt Centeno; Sheena Thomas; Laura Herdman; C Kotanidis; K Thomas; Brian P. Griffin; Scott D. Flamm; Alexios S. Antonopoulos; C Shirodaria; Nikant Sabharwal; John Deanfield; Stefan Neubauer; Jemma C. Hopewell; Keith M. Channon; Stephan Achenbach; Charalambos Antoniades
European Heart Journal | 2018
Ioannis Akoumianakis; Fabio Sanna; Marios Margaritis; Laura Herdman; Alexios S. Antonopoulos; Rana Sayeed; George Krasopoulos; Mario Petrou; Keith M. Channon; Charalambos Antoniades
European Heart Journal | 2018
Ioannis Akoumianakis; Alexios S. Antonopoulos; Laura Herdman; Marios Margaritis; Evangelos Oikonomou; George Krasopoulos; Mario Petrou; Rana Sayeed; Keith M. Channon; Charalambos Antoniades